Additionally, exenatide also dose-dependently attenuated the proliferation of breast cancer cells in vitro and in vivo by inhibiting the activation of NF-κB and suppressing the proliferation, invasion, migration, and epithelial-to-mesenchymal transition of glioma cells by GLP-1R/sirt3 pathway [187,188]. Here, GLP1R is linked to breast cancer.